Codexis Price to Sales Ratio 2009-2021 | CDXS

Historical PS ratio values for Codexis (CDXS) over the last 10 years. The current P/S ratio for Codexis as of January 19, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Codexis P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-01-20 20.79 13.22
2021-09-30 23.26 $1.57 14.79
2021-06-30 22.66 $1.34 16.90
2021-03-31 22.89 $1.20 19.08
2020-12-31 21.83 $1.17 18.68
2020-09-30 11.74 $1.14 10.26
2020-06-30 11.40 $1.19 9.58
2020-03-31 11.16 $1.16 9.62
2019-12-31 15.99 $1.20 13.34
2019-09-30 13.72 $1.18 11.66
2019-06-30 18.43 $1.14 16.23
2019-03-31 20.53 $1.17 17.58
2018-12-31 16.70 $1.17 14.27
2018-09-30 17.15 $1.33 12.87
2018-06-30 14.40 $1.22 11.77
2018-03-31 11.00 $1.19 9.27
2017-12-31 8.35 $1.09 7.66
2017-09-30 6.65 $0.87 7.69
2017-06-30 5.45 $1.01 5.39
2017-03-31 4.80 $1.18 4.08
2016-12-31 4.60 $1.18 3.89
2016-09-30 4.44 $1.23 3.61
2016-06-30 4.03 $1.30 3.09
2016-03-31 3.11 $1.07 2.90
2015-12-31 4.23 $1.05 4.04
2015-09-30 3.39 $1.12 3.01
2015-06-30 3.89 $0.89 4.35
2015-03-31 4.56 $0.91 4.99
2014-12-31 2.52 $0.92 2.73
2014-09-30 2.33 $0.80 2.91
2014-06-30 1.46 $0.71 2.06
2014-03-31 2.04 $0.72 2.84
2013-12-31 1.40 $0.84 1.67
2013-09-30 1.76 $0.81 2.19
2013-06-30 2.21 $1.41 1.57
2013-03-31 2.39 $1.86 1.29
2012-12-31 2.21 $2.42 0.91
2012-09-30 3.03 $3.14 0.96
2012-06-30 3.71 $3.36 1.10
2012-03-31 3.65 $3.46 1.06
2011-12-31 5.30 $3.48 1.52
2011-09-30 4.57 $3.75 1.22
2011-06-30 9.63 $3.62 2.66
2011-03-31 11.82 $3.81 3.10
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.394B $0.069B
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis? proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.655B 9.08
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.351B 19.22
Biohaven Pharmaceutical Holding (BHVN) United States $7.535B 0.00
Emergent Biosolutions (EBS) United States $2.453B 8.82
Arcus Biosciences (RCUS) United States $2.353B 0.00
Myovant Sciences (MYOV) United Kingdom $1.344B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.156B 0.00
Zymeworks (ZYME) Canada $0.627B 0.00
Ambrx Biopharma (AMAM) United States $0.207B 0.00
SQZ Biotechnologies (SQZ) United States $0.207B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81